HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model

This publication has 34 references indexed in Scilit:

• To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives
  Advanced Drug Delivery Reviews, 2021
• Monitoring cell endocytosis of liposomes by real-time electrical impedance spectroscopy
  Analytical and Bioanalytical Chemistry, 2020
• Revisiting the use of sPLA 2 -sensitive liposomes in cancer therapy
  Journal of Controlled Release, 2017
• Predicting the influence of liposomal lipid composition on liposome size, zeta potential and liposome-induced dendritic cell maturation using a design of experiments approach
  European Journal of Pharmaceutics and Biopharmaceutics, 2015
• Her2-targeted pegylated liposomal doxorubicin: Retention of target-specific binding and cytotoxicity after in vivo passage
  Journal of Controlled Release, 2009
• Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells
  Pharmaceutical Research, 2007
• Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers
  Biochimie, 2005
• Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma
  Cancer Chemotherapy and Pharmacology, 2003
• Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets
  International Journal of Cancer, 2002
• In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release
  Biochimica et Biophysica Acta (BBA) - Biomembranes, 1992